Brief: Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial To Treat Hematologic Cancers Resumes Patient Enrollment

Decoy Therapeutics

03/01/2024 14:28

Jan 3 (Reuters) - Salarius Pharmaceuticals Inc  SLRX.O :
    * INVESTIGATOR-INITIATED PHASE 1/2 CLINICAL TRIAL USING
SALARIUS
PHARMACEUTICALS’ SECLIDEMSTAT IN COMBINATION WITH AZACITIDINE TO
TREAT HEMATOLOGIC CANCERS RESUMES PATIENT ENROLLMENT
    * FDA HAS REMOVED PARTIAL CLINICAL HOLD ON MD ANDERSON TRIAL
WITH
SECLIDEMSTAT IN BLOOD CANCERS
    * ADDITIONAL PATIENT SHOWED PARTIAL RESPONSE, BRINGING
OBJECTIVE
RESPONSE RATE IN EWING SARCOMA FIRST-RELAPSE PATIENTS TO 60%

Source text for Eikon:  ID:nGNX6fpnC 
Further company coverage:  SLRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))